 STAMFORD, Conn., June 16, 2021 GLOBE NEWSWIRE -- SpringWorks Therapeutics, Inc. Nasdaq: SWTX, a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today reported the initiation of a Phase 12 clinical trial to evaluate mirdametinib, an investigational MEK inhibitor, for the treatment of children, adolescents, and young adults with low-grade glioma LGG. The study is sponsored by St. Jude Childrens Research Hospital. More information on the trial can be found on under the identifier NCT04923126. 